Wednesday, October 29, 2014 9:51:22 PM
I sometimes have age related memory problems myself, so I don't mean to make light of it, but it's usually just names and words with me. Some people need more repetition on the details, constant reminders so they (we) can keep the faith.
It's not easy being relatively level on the share price like big board stocks, but the alternative is seen on almost every other penny stock. That would be dilution and falling prices, with the shareholders footing the bill for growth. The CMGO team is trying hard to avoid dilution, including deferring CEO salaries until the share price is up. Then he profits only when we profit, not before, like most penny stock CEO's, including our recent spin-off.
I love a CEO that has faith in the share price and takes his rewards in company shares, not cash. That's one of several reasons I like to hold this stock long term. The CEO is confident in longer term success.
Let's see if I can remember (LOL) what needs to be addressed. It's the reasons for concentrating on XA and GG now and waiting on CMGO promotion until the growth records are behind us and well documented. We need to promote CMGO based on both sides of the coin, future plans AND proven track record, while showing current growth...that's actually three dimensional, and not just pumped promises for the future alone. What else?
"It's not your thinking that makes you money, it's your sitting." - Jesse Livermore
Recent CMGO News
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 11/17/2023 02:59:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:02:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/15/2023 08:05:48 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM